Table 2.
Prevalence of autoantibodies in myositis subsets.
| MSA IIM Subtype |
Sensitivity IIM Subtype n pos, % ( 95% CI) |
Specificity IIM Subtype n pos, % (95% CI) |
Odds Ratio (95% CI) |
|---|---|---|---|
| Jo-1 (ASS) | 48/67 71.6 (59.9–81.0) |
4/197 98.0 (94.9–99.2) |
121.9 (40.8–360.0) |
| PL-7 (ASS) | 7/67 10.4 (5.2–20.0) |
0/197 100.0 (98.1–100.0) |
45.9 (2.6–821.9) |
| PL-12 (ASS) | 5/67 7.5 (3.2–16.3) |
0/197 100.0, 98.1–100.0 |
79.4 (0.9–6999.1) |
| EJ (ASS) | 2/67 3.0 (0.8–10.2) |
1/197 99.5 (97.2–99.9) |
6.0 (0.7–46.8) |
| Mi-2 (DM) | 15/70 21.4 (13.4–32.4) |
4/194 97.9 (94.8–99.2) |
13.0 (4.3–38.7) |
| NXP2 (DM) | 5/70 7.1 (3.1–15.7) |
3/194 98.5 (95.6–99.5) |
4.9 (1.3–19.1) |
| SAE (DM) | 8/70 11.4 (5.9–21.0) |
2/194 99.0 (96.3–99.7) |
12.4 (2.9–52.9) |
| TIF1γ (DM) | 11/70 15.7 (9.0- 26.0) |
28/194 85.6 (79.9–89.8) |
4.8 (1.7–13.0) |
| TIF1γ (cDM ) | 22/35 62.9 (46.3–76.8) |
17/229 92.6 (88.4–95.3) |
43.2 (15.1–122.8) |
| MDA5 (CADM) | 15/21 71.4 (50.0–86.2) |
7/243 97.1 (94.2–98.6) |
84.3 (25.7–277.5) |
| HMGCR (IMNM) | 8/16 50.0 (28.0–72.0) |
8/248 96.8 (93.8–98.4) |
30.0 (9.2–98.2) |
| SRP (IMNM) | 2/16 12.5 (35.0–36.0) |
3/248 98.8 (96.5–99.6) |
11.7 (2.15–64.41) |
Abbreviations: ASS = antisynthetase syndrome; CADM = clinically amyopathic dermatomyositis; cDM = cancer-associated dermatomyositis; IMNM = immune-mediated necrotizing myopathy; MDA5 = Melanoma differentiation-associated protein 5; NXP2 = nuclear matrix protein 2; SAE = small ubiquitin-like modifier activating enzyme; SRP = signal recognition particle; TIF1γ = transcriptional intermediary factor 1 gamma.